Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Share:
Related TEVA
Benzinga's M&A Chatter for Wednesday May 27, 2015
Report: Mylan Could See Sweetened Bid From Teva Pharmaceutical
Teva Settles Provigil Drug Delay Charge with FTC for $1.2B - Analyst Blog (Zacks)
Related NVS
Novartis Reports Two Positive US Phase III Programs in COPD for QVA149, NVA237
Novartis Posts Higher Q1 Profit
Juno Therapeutics, Editas Ink Cancer Immunotherapy Deal - Analyst Blog (Zacks)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Related Articles (TEVA + NVS)

Around the Web, We're Loving...